Author:
Kato Renpei,Matsuura Tomohiko,Maekawa Shigekatsu,Kato Yoichiro,Kanehira Mitsugu,Takata Ryo,Obara Wataru
Subject
Pharmacology,Immunology,Immunology and Allergy
Reference30 articles.
1. Cancer statistics, 2020;Siegel;CA Cancer J Clin,2020
2. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial;Motzer;Lancet Oncology,2019
3. Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy;Pires da Silva;Cancer,2020
4. Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma;Lee;Pigment Cell Melanoma Res,2018
5. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis;Bianchi;Ann. Oncol.,2012
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献